应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01093 石药集团
未开盘 10-06 16:08:03
10.000
+0.145
+1.47%
最高
10.110
最低
9.855
成交量
3,650万
今开
9.995
昨收
9.855
日振幅
2.59%
总市值
1,152亿
流通市值
1,152亿
总股本
115.22亿
成交额
3.65亿
换手率
0.32%
流通股本
115.22亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
石药集团(01093)：8项最新临床试验进展将于2026年欧洲肿瘤内科学会(ESMO)年会上发布
智通财经 · 10-05 18:58
石药集团(01093)：8项最新临床试验进展将于2026年欧洲肿瘤内科学会(ESMO)年会上发布
石药集团（01093）8项肿瘤创新成果将亮相2026年ESMO年会 两项入选“突破性摘要”
公告速递 · 10-05 18:55
石药集团（01093）8项肿瘤创新成果将亮相2026年ESMO年会 两项入选“突破性摘要”
【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显
金吾财讯 · 10-05 08:50
【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显
石药集团2026年9月股份变动月报：股本维持不变
公告速递 · 10-02
石药集团2026年9月股份变动月报：股本维持不变
异动解读｜石药集团盘中下跌3.13%，报9.72港元
行情直击 · 10-02
异动解读｜石药集团盘中下跌3.13%，报9.72港元
石药集团(01093)：依达格鲁肽α注射液联合二甲双胍治疗中国成人2型糖尿病患者的III期临床研究结果于2026年第62届欧洲糖尿病研究协会年会(EASD 2026)上以简短口头讨论形式公布
智通财经 · 09-30
石药集团(01093)：依达格鲁肽α注射液联合二甲双胍治疗中国成人2型糖尿病患者的III期临床研究结果于2026年第62届欧洲糖尿病研究协会年会(EASD 2026)上以简短口头讨论形式公布
ETF异动 | AI制药赛道热度高涨 华夏恒生生科(03069)盘中涨超4% 华夏创新药(03525)午后涨超3%
智通财经 · 09-30
ETF异动 | AI制药赛道热度高涨 华夏恒生生科(03069)盘中涨超4% 华夏创新药(03525)午后涨超3%
港股三大指数拉升转涨
格隆汇 · 09-30
港股三大指数拉升转涨
创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链
金吾财讯 · 09-30
创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链
港股异动 | 石药集团(01093)涨近6% 接连披露多项研发进展 涉及mRNA肿瘤疫苗、重组蛋白疫苗等方向
智通财经 · 09-30
港股异动 | 石药集团(01093)涨近6% 接连披露多项研发进展 涉及mRNA肿瘤疫苗、重组蛋白疫苗等方向
异动解读｜石药集团盘中上涨3.48%，带状疱疹疫苗获美国FDA临床试验批准
行情直击 · 09-30
异动解读｜石药集团盘中上涨3.48%，带状疱疹疫苗获美国FDA临床试验批准
石药集团(01093)重组带状疱疹疫苗获美国FDA临床试验批准
公告速递 · 09-29
石药集团(01093)重组带状疱疹疫苗获美国FDA临床试验批准
石药集团(01093.HK)：SYS 6077注射液在中国获临床试验批准
智通财经 · 09-28
石药集团(01093.HK)：SYS 6077注射液在中国获临床试验批准
石药集团（01093）宣布SYS 6077注射液获中国临床试验批准
公告速递 · 09-28
石药集团（01093）宣布SYS 6077注射液获中国临床试验批准
石药集团：贝莱德减持，好仓比例降至4.99%
港股披露 · 09-28
石药集团：贝莱德减持，好仓比例降至4.99%
智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%
智通财经 · 09-25
智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%
石药集团(01093)：JMT101联合奥希替尼一线治疗携带EGFR20号外显子插入突变的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验取得阳性顶线结果
智通财经 · 09-24
石药集团(01093)：JMT101联合奥希替尼一线治疗携带EGFR20号外显子插入突变的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验取得阳性顶线结果
石药集团（01093）公布JMT101联合奥希替尼一线治疗EGFR ex20ins NSCLC三期试验达主要终点
公告速递 · 09-24
石药集团（01093）公布JMT101联合奥希替尼一线治疗EGFR ex20ins NSCLC三期试验达主要终点
石药集团（01093）在华启动HB1801治疗晚期乳腺癌Ⅲ期临床
公告速递 · 09-24
石药集团（01093）在华启动HB1801治疗晚期乳腺癌Ⅲ期临床
石药集团(01093.HK)：注射用多西他赛(白蛋白结合型)(HB1801)用于治疗晚期乳腺癌的Ⅲ期临床试验在中国正式启动
智通财经 · 09-24
石药集团(01093.HK)：注射用多西他赛(白蛋白结合型)(HB1801)用于治疗晚期乳腺癌的Ⅲ期临床试验在中国正式启动
暂无数据
公司概况
公司名称：
石药集团
所属市场：
SEHK
上市日期：
--
主营业务：
石药集团有限公司是一家主要从事药品的生产及销售的公司。该公司主要从事成药业务、原料产品业务、功能食品及其他业务。该公司的产品主要涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢以及其他治疗领域。该公司的产品销往国内外市场。
发行价格：
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":10,"timestamp":1791274083002,"preClose":9.855,"halted":0,"volume":36500954,"delay":0,"changeRate":0.014713343480466724,"floatShares":11522000000,"shares":11522000000,"eps":0.3978751224259166,"marketStatus":"未开盘","change":0.145,"latestTime":"10-06 16:08:03","open":9.995,"high":10.11,"low":9.855,"amount":365093232,"amplitude":0.025875,"askPrice":10.01,"askSize":178000,"bidPrice":10,"bidSize":118000,"shortable":3,"etf":0,"ttmEps":0.7616919938630085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791336600000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":9.855,"dividendRate":0.033769,"openAndCloseTimeList":[[1791250200000,1791259200000],[1791262800000,1791273600000]],"volumeRatio":0.499795,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":false,"expireDate":1806336000000,"strike":"7.25","timestamp":1791265176156,"price":0.25,"volume":400,"amount":200000,"type":"*"},{"symbol":"CSP.HK","call":false,"expireDate":1806336000000,"strike":"7.50","timestamp":1791265176153,"price":0.3,"volume":400,"amount":240000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.2751,"impliedVolPercentile":0.0041},"requestUrl":"/m/hq/s/01093/tweets","defaultTab":"tweets","newsList":[{"id":"2673728701","title":"石药集团(01093)：8项最新临床试验进展将于2026年欧洲肿瘤内科学会(ESMO)年会上发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2673728701","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673728701?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:58","pubTimestamp":1791197912,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，集团将于2026年10月23日至10月27日在西班牙马德里召开的欧洲肿瘤内科学会(ESMO)年会上展示8项最新临床试验进展，其中2项入选最新突破性摘要(Late-breaking Abstract, LBA)。本次入选的8项临床进展将分别以1项优选口头报告、3项快速口头报告、3项壁报及1项电子壁报的形式展示，覆盖乳腺癌、肺癌、胃癌、肝癌、结肠癌、胰腺癌、血管周围上皮样细胞瘤等瘤种，充分体现了集团在肿瘤治疗领域的研发实力与临床研究能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","KURE","LU1226287529.USD","LU1226288253.USD","LU2039709279.SGD","LU0501845795.SGD","SG9999004220.SGD","LU0326950275.SGD","MDTX","LU1152091168.USD","LU1008478684.HKD","LU1226287875.USD","IE0008368742.USD","LU1960683339.HKD","BK1515","IE00B031HY20.USD","LU0140636845.USD","LU0880133367.SGD","LU1152091754.HKD","PSYK","IE0008369823.USD","BK1191","IE00B543WZ88.USD","BMED","01093","LU0072913022.USD","LU1328277881.USD","LU0067412154.USD","LU0314109678.HKD","LU1226287792.SGD","LU1951186391.HKD","LU1807302812.USD","LU1993786604.SGD","LU1813983027.USD","HK0000165453.HKD","IBBQ","LU0315179316.USD","IBBJ","IE00BZ08YT58.USD","BK1521","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138420406","title":"石药集团（01093）8项肿瘤创新成果将亮相2026年ESMO年会 两项入选“突破性摘要”","url":"https://stock-news.laohu8.com/highlight/detail?id=1138420406","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138420406?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:55","pubTimestamp":1791197739,"startTime":"0","endTime":"0","summary":"石药集团10月5日发布自愿公告称，公司及其附属公司共8项最新肿瘤领域临床试验进展将于2026年10月23日至27日在西班牙马德里举行的欧洲肿瘤内科学会年会上集中展示，其中2项被大会选为“最新突破性摘要”。该适应症已于2026年5月获NMPA批准上市。HB1901于2025年2月获NMPA授予BTD。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","01093","06160","HK0000165453.HKD","LU0244354667.USD","LU1794554557.SGD","LU2242644610.SGD","600109","MEDX","LU1226287875.USD","01877","01177","02269","06978","LU2399975544.HKD","LU1242518931.SGD","IE0008368742.USD","LU1807302812.USD","09688","LU0823426308.USD","BK1515","KURE","LNGR","BK1610","09926","BK1576","LU0315179316.USD","LU1226288253.USD","LU1328277881.USD","LU0856984785.SGD","KCE","LU0455707207.USD","LU0516422952.EUR","LU0314109678.HKD","LU0211977185.USD","LU0823426480.USD","BK0201","09995","02616","LU0052750758.USD","BK1583","06185","IBBQ","LU0359202008.SGD","LU0540923850.HKD","02142","BK1161","159992","01801","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133020125","title":"石药集团2026年9月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1133020125","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133020125?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:42","pubTimestamp":1790937743,"startTime":"0","endTime":"0","summary":"石药集团于2026年10月2日发布的月度报告显示，截至2026年9月30日，公司已发行股份总数维持在11,522,451,732股，与上月底保持一致，未发生增发、回购或注销等变动，库藏股数量也保持为0股。在指标方面，石药集团另披露，2015年及2026年购股权计划下的股份期权数量未发生变化，其中2026年5月28日生效的购股权计划在本月底的期权结存数为1,152,245,173份。石药集团表示，将持续严格遵循香港联交所相关上市规则和法律法规的要求，确保后续信息披露的准确与及时。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199231751","title":"异动解读｜石药集团盘中下跌3.13%，报9.72港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199231751","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199231751?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:46","pubTimestamp":1790905619,"startTime":"0","endTime":"0","summary":"10月2日，石药集团盘中下跌3.13%，报9.72港元/股，成交额6682.96万港元。石药集团所在的制药行业整体走弱，个股中，翰森制药跌4.31%，恒瑞医药跌4.26%，中国生物制药跌3.77%，凯莱英跌5.28%，先声药业跌4.73%。石药集团有限公司是一家主要从事药品的生产及销售的公司，产品主要涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢以及其他治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671920128","title":"石药集团(01093)：依达格鲁肽α注射液联合二甲双胍治疗中国成人2型糖尿病患者的III期临床研究结果于2026年第62届欧洲糖尿病研究协会年会(EASD 2026)上以简短口头讨论形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2671920128","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671920128?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:11","pubTimestamp":1790770280,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团已于2026年第62届欧洲糖尿病研究协会年会上，以简短口头讨论形式公布本集团研发的胰高血糖素样肽-1受体激动剂依达格鲁肽α注射液联合二甲双胍治疗中国成人2型糖尿病患者III期临床研究(该研究)的阳性结果。该研究结果表明，TG103注射液在该人群中展现出良好的疗效和安全性。TG103注射液各剂量组的低血糖发生率以及因不良事件导致的停药率均相对较低，且均未报告严重低血糖事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：依达格鲁肽α注射液联合二甲双胍治疗中国成人2型糖尿病患者的III期临床研究结果于2026年第62届欧洲糖尿病研究协会年会(EASD 2026)上以简短口头讨论形式公布","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU0501845795.SGD","BK1191","LU1152091168.USD","LU1960683339.HKD","BK1521","LU0072913022.USD","IE00BZ08YT58.USD","LU1226287875.USD","IE00B031HY20.USD","LU1226287529.USD","LU0314109678.HKD","LU1008478684.HKD","LU1807302812.USD","LU1152091754.HKD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","LU0067412154.USD","KURE","LU0326950275.SGD","LU1226287792.SGD","LU0880133367.SGD","LU0140636845.USD","LU1226288253.USD","IE00B543WZ88.USD","BK1515","LU1951186391.HKD","SG9999004220.SGD","LU1328277881.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU0315179316.USD","01093","LU1226288170.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671278515","title":"ETF异动 | AI制药赛道热度高涨 华夏恒生生科(03069)盘中涨超4% 华夏创新药(03525)午后涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671278515","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671278515?lang=zh_cn&edition=full","pubTime":"2026-09-30 13:44","pubTimestamp":1790747084,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，AI制药ETF延续近期涨势，截至发稿，华夏恒生生科涨3.58%，报16.8港元；华夏创新药涨2.95%，报10.48港元。消息面上，AI制药赛道热度高涨，AI4S正从“算力与模型”加速走向生物医药产业兑现。由OpenAI参投的生物科技初创公司Red Queen Bio计划于明年正式启动抗体药物的人体试验。同日，金斯瑞与礼来AI药物发现平台达成协作，公开资料显示，华夏恒生生科聚焦港股生物科技产业链，较大比例布局生命科学工具及服务企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","BK1576","IE00BZ08YS42.EUR","KURE","BK4550","LU1226287529.USD","LU2039709279.SGD","QTOC","LU0501845795.SGD","SG9999004220.SGD","LU0326950275.SGD","LU1152091168.USD","03069","LU1226287875.USD","IE0008368742.USD","01477","LU1960683339.HKD","03525","IE00B031HY20.USD","LU1152091754.HKD","BK1610","VTHR","FDN","HK0000320223.HKD","IE0008369823.USD","LU0359201885.HKD","BK1191","IE00B543WZ88.USD","LU0072913022.USD","01093","LU1951186391.HKD","LU0067412154.USD","LU0314109678.HKD","LU0359202008.SGD","LU1226287792.SGD","LU1807302812.USD","LU1993786604.SGD","LU1813983027.USD","HK0000165453.HKD","HK0000306685.HKD","ARTY","01276","AGIX","IE00BZ08YT58.USD","AIPO","BK4585","BK1521","IE00B5MMRT66.SGD","CHAT","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671934224","title":"港股三大指数拉升转涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2671934224","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671934224?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:57","pubTimestamp":1790737054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","LU0072913022.USD","LU0501845795.SGD","LU1226287529.USD","LU1960683339.HKD","HK0000165453.HKD","LU1226288170.HKD","BK1574","LU1152091168.USD","LU1152091754.HKD","LU0140636845.USD","LU0314109678.HKD","LU1328277881.USD","01276","LU1226287875.USD","IE0008369823.USD","IE00B5MMRT66.SGD","KURE","LU1023057109.AUD","LU2039709279.SGD","SG9999004220.SGD","BK1583","BK1191","IE00B543WZ88.USD","BK1521","BK1515","IE00BZ08YT58.USD","LU1813983027.USD","01093","06978","LU0359201612.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU1226288253.USD","IE0008368742.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU2543165471.USD","01952","LU0067412154.USD","LU0359201885.HKD","LU1807302812.USD","LU1008478684.HKD","IE00B031HY20.USD","LU0359202008.SGD","LU1993786604.SGD","LU0326950275.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222418","title":"创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222418","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222418?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:35","pubTimestamp":1790735739,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，金斯瑞生物科技 涨10.10%，石药集团涨6.07%，云顶新耀涨5.79%，恒瑞医药涨5.18%，药明合联涨4.48%，晶泰控股涨4.06%，乐普生物涨3.52%，药明生物涨3.46%。消息面上，开源证券表示，整体上，持续看好创新药及其产业链及AI、脑机接口、生物制造等国家战略新兴产业。后续可重点跟踪ESMO临床数据、三季度订单及业绩验证和政策细则落地，积极把握优质创新药、CXO及生命科学上游调整后的配置机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992823","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","LU1242518931.SGD","LU1328277881.USD","IE00BZ08YT58.USD","LU1008478684.HKD","BK1141","159992","01276","IE00BZ08YR35.GBP","LU0039217434.USD","HK0000306701.USD","LU0823426480.USD","02228","LU0072913022.USD","LU0540923850.HKD","LU1188198961.HKD","LU0880133367.SGD","KURE","LU0140636845.USD","LU0708995153.HKD","SG9999004220.SGD","BK1515","01952","LU0359201885.HKD","06978","LU0516422366.SGD","LU1813983027.USD","BK1610","01093","MEDX","LU0348827113.USD","LU1242518857.USD","BK1521","BK1589","IE00B0JY6N72.USD","02269","LU0029874905.USD","LU0128522744.USD","LU0307460666.USD","LU1807302812.USD","LU1688375341.USD","IBBQ","LU0181495838.USD","BK1161","01548","LNGR","BK1574","02268","LU1880383366.USD","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221719","title":"港股异动 | 石药集团(01093)涨近6% 接连披露多项研发进展 涉及mRNA肿瘤疫苗、重组蛋白疫苗等方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221719","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671221719?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:24","pubTimestamp":1790735081,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团涨近6%，截至发稿，涨5.86%，报10.03港元，成交额4.02亿港元。消息面上，9月28日至29日，石药集团连续披露多项研发进展，涉及mRNA肿瘤疫苗、重组蛋白疫苗及肥胖症治疗等方向。此前9月28日晚，石药集团公告，其开发的SYS 6077注射液已获中国国家药品监督管理局批准签发药物临床试验批准通知书，可在中国开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287875.USD","LU2039709279.SGD","BK4585","BK1515","IE00B543WZ88.USD","LU1226287529.USD","LU0501845795.SGD","IE00B031HY20.USD","LU0315179316.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1993786604.SGD","HK0000165453.HKD","LU1152091754.HKD","SG9999004220.SGD","BK1191","LU0072913022.USD","IE00BZ08YT58.USD","LU0067412154.USD","LU1226288170.HKD","LU1951186391.HKD","LU0326950275.SGD","IE00BZ08YS42.EUR","LU1328277881.USD","LU0314109678.HKD","LU1807302812.USD","VXUS","BK4588","KURE","IE0008369823.USD","LU0880133367.SGD","LU1226288253.USD","LU1226287792.SGD","LU1813983027.USD","LU1152091168.USD","01093","LU0140636845.USD","159646","IE0008368742.USD","BK1521","IE00BZ08YR35.GBP","LU1960683339.HKD","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119815064","title":"异动解读｜石药集团盘中上涨3.48%，带状疱疹疫苗获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1119815064","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119815064?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:45","pubTimestamp":1790732718,"startTime":"0","endTime":"0","summary":"9月30日，石药集团盘中上涨3.48%，报9.8港元，成交额1.09亿港元。消息面上，公司9月29日连发两项研发进展公告：其自主研发的重组带状疱疹疫苗SYS6052获美国FDA批准在美国开展临床试验，该疫苗此前已于7月获中国NMPA批准开展国内临床，此次为公司在重组蛋白疫苗领域首获美国临床许可，标志着预防性疫苗全球化布局正式启动；同日，公司减重药物JMT206注射液在中国首家研究中心启动Ib期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团拉升，带状疱疹疫苗获美国临床批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193918647","title":"石药集团(01093)重组带状疱疹疫苗获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1193918647","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193918647?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:05","pubTimestamp":1790676344,"startTime":"0","endTime":"0","summary":"石药集团有限公司(01093)9月29日公告称，其自主研发的1类新药重组带状疱疹疫苗(SYS 6052)已获得美国食品药品监督管理局(FDA)批准，可在美国开展临床研究。\n该产品由水痘-带状疱疹病毒gE蛋白抗原与公司自主开发的新型纳米佐剂系统组成，临床适应症为50岁及以上成人，用于预防带状疱疹及其并发症。\n公告显示，SYS 6052此前已于2026年7月获得中国国家药品监督管理局(NMPA)批准在国内开展临床试验。本次获批为石药集团在重组蛋白疫苗领域取得的首个美国临床试验许可。\n公司表示，此次获批为包括重组带状疱疹疫苗在内的预防性疫苗产品的全球开发奠定了基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236373","title":"石药集团(01093.HK)：SYS 6077注射液在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236373","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670236373?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:11","pubTimestamp":1790590293,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0314109678.HKD","LU0315179316.USD","LU1152091754.HKD","LU1226287529.USD","LU0072913022.USD","LU1008478684.HKD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1226287875.USD","LU1226287792.SGD","LU0326950275.SGD","IE00B031HY20.USD","LU1813983027.USD","LU1993786604.SGD","HK0000165453.HKD","SG9999004220.SGD","LU0140636845.USD","BK1191","IE00BZ08YR35.GBP","IE0008368742.USD","IE00BZ08YT58.USD","LU1226288170.HKD","KURE","IE00B5MMRT66.SGD","LU1226288253.USD","LU0880133367.SGD","LU1807302812.USD","LU0067412154.USD","01093","LU1328277881.USD","LU2039709279.SGD","BK1521","LU0501845795.SGD","LU1152091168.USD","LU1951186391.HKD","IE0008369823.USD","IE00B543WZ88.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140180155","title":"石药集团（01093）宣布SYS 6077注射液获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1140180155","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140180155?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:11","pubTimestamp":1790590265,"startTime":"0","endTime":"0","summary":"2026年9月28日，石药集团有限公司发布自愿公告称，其自主开发的SYS 6077注射液已获国家药品监督管理局签发药物临床试验批准通知书，可在中国开展针对晚期恶性肿瘤的临床试验。公司在公告中披露，临床前研究结果显示，SYS 6077能够诱导针对多种肿瘤抗原的T细胞免疫反应，并在多个临床前肿瘤模型中展示抗肿瘤活性。石药集团表示，SYS 6077临床试验的获批标志着公司在mRNA技术和肿瘤免疫领域迈出关键一步，有望为晚期恶性肿瘤患者提供新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160507551","title":"石药集团：贝莱德减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160507551","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160507551?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:41","pubTimestamp":1790588462,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月23日通过出售场外差价合约（CFDs）减持石药集团股份，涉及股数258.40万股。该笔交易属场外衍生品交易，并非在二级市场直接买卖正股。贝莱德此次减持前持有石药集团好仓5.79亿股，占比5.02%；减持后持股量为5.76亿股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670352419","title":"智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670352419","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670352419?lang=zh_cn&edition=full","pubTime":"2026-09-25 07:52","pubTimestamp":1790293960,"startTime":"0","endTime":"0","summary":"预计本公司将于2026年12月31日前与相关方订立合伙协议及附属协议。 海光芯正：下半年1.6T光模块开始出货 南向持股占比升至4.2%海光芯正在9月9日至11日举行的第27届中国国际光电博览会上，展出全栈自研硅光1.6T光模块和6.4T NPO。此外，南向资金近期持续加仓，海光芯正已于今年9月7日起纳入港股通。截至目前，南向资金持有海光芯正384.44万股，占公司已发行普通股的4.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","LU1152091754.HKD","LU1008478684.HKD","KCAI","01191","LU1206782309.USD","03692","03933","LU0173614495.USD","LU0287142896.SGD","IE00B543WZ88.USD","LU1226287875.USD","02628","LU1152091168.USD","SG9999012710.SGD","00659","KURE","LU0320764599.SGD","LU0140636845.USD","LU0326950275.SGD","VXUS","BK1170","FLHK","LU0708995583.HKD","LU1960683339.HKD","01093","BK1230","IE00B3M56506.USD","BK1521","BK1589","LU0211977185.USD","BK1537","IE00B5MMRT66.SGD","LU2097828714.EUR","IE00B031HY20.USD","LU0307460666.USD","LU0871576103.HKD","LU1226287529.USD","SG9999003461.SGD","IE0032431581.USD","01133","LU0067412154.USD","LU0315179316.USD","BK4550","LU1226287792.SGD","BK1205","BK1550","LU1046422090.SGD","FDN","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669988174","title":"石药集团(01093)：JMT101联合奥希替尼一线治疗携带EGFR20号外显子插入突变的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验取得阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669988174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669988174?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:24","pubTimestamp":1790252678,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的贝柯妥塔单抗联合奥希替尼一线治疗携带表皮生长因子受体20号外显子插入突变的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验，在预设的期中分析中达到主要终点，取得阳性顶线结果。该试验是一项随机、开放、平行对照的Ⅲ期临床试验，旨在比较该产品联合奥希替尼与铂类联合培美曲塞在上述患者一线治疗中的有效性及安全性。此外，该联合治疗方案的安全性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0072913022.USD","BK1521","PSYK","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","IBBQ","LU0140636845.USD","MDTX","LU1993786604.SGD","IE00BZ08YT58.USD","BMED","LU0326950275.SGD","BK1191","LU1226288170.HKD","LU1008478684.HKD","LU1813983027.USD","LU1328277881.USD","LU1226287875.USD","IBBJ","IE0008368742.USD","LU1226287792.SGD","LU1152091168.USD","LU1226287529.USD","BK1515","KURE","LU0880133367.SGD","LU1807302812.USD","IE00B031HY20.USD","LU0315179316.USD","LU1960683339.HKD","HK0000165453.HKD","LU0314109678.HKD","IE0008369823.USD","LU1226288253.USD","SG9999004220.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199046574","title":"石药集团（01093）公布JMT101联合奥希替尼一线治疗EGFR ex20ins NSCLC三期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1199046574","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199046574?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:11","pubTimestamp":1790251919,"startTime":"0","endTime":"0","summary":"石药集团有限公司9月24日发布自愿公告称，公司自主开发的贝柯妥塔单抗联合奥希替尼用于一线治疗携带表皮生长因子受体20号外显子插入突变的局部晚期或转移性非小细胞肺癌的Ⅲ期临床试验，在预设的期中分析中达到主要终点，取得阳性顶线结果。EGFR ex20ins为除EGFR经典突变外最常见的EGFR基因突变类型，患者普遍面临高肿瘤负荷、脑转移发生率高及预后不佳等挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132367197","title":"石药集团（01093）在华启动HB1801治疗晚期乳腺癌Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1132367197","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132367197?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:09","pubTimestamp":1790240946,"startTime":"0","endTime":"0","summary":"石药集团有限公司9月24日发布自愿公告称，公司自主研发的注射用多西他赛治疗晚期乳腺癌的Ⅲ期临床试验已于近期在中国首家研究中心正式启动。\\n\\nHB1801是公司纳米药物技术平台开发的代表性产品，将多西他赛包裹于人血白蛋白中。\\n\\nHB1801-017为一项随机、开放、 multicenter 的Ⅲ期临床试验，旨在比较HB1801与多西他赛（泰索帝）在晚期乳腺癌受试者中的疗效和安全性。\\n\\n公司表示，此次Ⅲ期临床试验的正式启动，标志着HB1801在晚期乳腺癌治疗领域的开发迈入关键阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152465","title":"石药集团(01093.HK)：注射用多西他赛(白蛋白结合型)(HB1801)用于治疗晚期乳腺癌的Ⅲ期临床试验在中国正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152465","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669152465?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:02","pubTimestamp":1790240561,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1226288170.HKD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1008478684.HKD","LU1328277881.USD","IE00BZ08YR35.GBP","IE0008369823.USD","LU0314109678.HKD","LU1226287875.USD","IE00B543WZ88.USD","BK1191","LU1152091168.USD","LU0072913022.USD","LU0880133367.SGD","KURE","LU1951186391.HKD","LU0140636845.USD","LU0326950275.SGD","SG9999004220.SGD","BK1515","LU0501845795.SGD","LU1813983027.USD","LU1226288253.USD","LU1993786604.SGD","LU1960683339.HKD","01093","IE0008368742.USD","BK1521","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1807302812.USD","LU2039709279.SGD","LU1226287529.USD","LU0067412154.USD","HK0000165453.HKD","LU0315179316.USD","LU1226287792.SGD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.0495},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.2522},{"period":"6month","weight":0.0823},{"period":"1year","weight":0.0547},{"period":"ytd","weight":0.1953}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.0534},{"period":"3month","weight":0.0034},{"period":"6month","weight":-0.0572},{"period":"1year","weight":-0.0993},{"period":"ytd","weight":-0.0527}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品的生产及销售的公司。该公司主要从事成药业务、原料产品业务、功能食品及其他业务。该公司的产品主要涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢以及其他治疗领域。该公司的产品销往国内外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094313},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017543},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057684},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042479},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001853},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015989},{"month":8,"riseRate":0.454545,"avgChangeRate":0.011919},{"month":9,"riseRate":0.515152,"avgChangeRate":0.003046},{"month":10,"riseRate":0.545455,"avgChangeRate":0.00906},{"month":11,"riseRate":0.46875,"avgChangeRate":0.006831},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013329}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}